The goal of the Developmental Research Program in the Iowa Neuroendocrine Tumor SPORE is to bring new ideas and innovative techniques to bear on the diagnosis, curative therapy, and ultimately, the prevention of neuroendocrine tumors. The Developmental Research Program will provide up to $50,000 for one year ($25,000 from SPORE funds and a matching $25,000 from institutional resources) to each of two projects each year with the possibility of a second year of support based on progress. It is anticipated that support of developmental research projects will continue to result in the generation of new hypotheses that will be tested in full SPORE-sponsored projects or through peer reviewed external grant support. The long-term goal of the Iowa Neuroendocrine Tumor SPORE program is to translate the findings generated by developmental projects into an improved length and quality of life for patients with neuroendocrine tumors. More specifically, the objectives of the Developmental Research Program are to: (1) encourage innovative translational population, laboratory, and clinical studies in neuroendocrine tumors; (2) foster extensive collaboration between basic science, population science and clinical disciplines in translational research in neuroendocrine tumors; and, (3) generate new hypotheses to be tested in large-scale research projects or clinical trials that may lead to significant reduction in incidence and mortality of neuroendocrine tumors. Brief outlines of three potential developmental research projects are included to demonstrate the depth and breadth of ongoing research that can be applied to the translational research in neuroendocrine tumors and would be eligible for Iowa Neuroendocrine Tumor SPORE Developmental Program support. ?

Public Health Relevance

The Developmental Research Program in the Iowa Neuroendocrine Tumor SPORE will provide guidance from and collaboration with senior investigators, full access to SPORE shared resources, and financial support for early phase research that takes maximum advantage of SPORE resources to generate feasibility data for projects that have the highest translational potential. The SPORE Developmental Research Program encourages proposals from investigators in related disciplines so as to rapidly translate new treatment concepts to patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA174521-05
Application #
9756337
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2019-09-01
Budget End
2020-08-31
Support Year
5
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Iowa
Department
Type
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Mansour, John C; Chavin, Kenneth; Morris-Stiff, Gareth et al. (2018) Management of asymptomatic, well-differentiated PNETs: results of the Delphi consensus process of the Americas Hepato-Pancreato-Biliary Association. HPB (Oxford) :
Keck, Kendall J; Maxwell, Jessica E; Utria, Alan F et al. (2018) The Distal Predilection of Small Bowel Neuroendocrine Tumors. Ann Surg Oncol 25:3207-3213
Menda, Yusuf; Madsen, Mark T; O'Dorisio, Thomas M et al. (2018) 90Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy. J Nucl Med 59:1692-1698
Pelletier, Daniel J; Czeczok, Thomas W; Bellizzi, Andrew M (2018) A monoclonal antibody against SV40 large T antigen (PAb416) does not label Merkel cell carcinoma. Histopathology 73:162-166
Keck, Kendall J; Breheny, Patrick; Braun, Terry A et al. (2018) Changes in gene expression in small bowel neuroendocrine tumors associated with progression to metastases. Surgery 163:232-239
Lee, Dongyoul; Li, Mengshi; Bednarz, Bryan et al. (2018) Modeling Cell and Tumor-Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy. Radiat Res 190:236-247
Madsen, Mark T; Menda, Yusuf; O'Dorisio, Thomas M et al. (2018) Technical Note: Single time point dose estimate for exponential clearance. Med Phys 45:2318-2324
Czeczok, Thomas W; Stashek, Kristen M; Maxwell, Jessica E et al. (2018) Clusterin in Neuroendocrine Epithelial Neoplasms: Absence of Expression in a Well-differentiated Tumor Suggests a Jejunoileal Origin. Appl Immunohistochem Mol Morphol 26:94-100
Scott, Aaron T; Howe, James R (2018) Management of Small Bowel Neuroendocrine Tumors. J Oncol Pract 14:471-482
Strosberg, Jonathan; Wolin, Edward; Chasen, Beth et al. (2018) Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial. J Clin Oncol 36:2578-2584

Showing the most recent 10 out of 24 publications